OTCBB ALERTS

[Mandroid]

SCII-- 1.0 -- WOW - Stem Cell Therapy International, Inc., a leading company in the field of research and development of stem
cell transplantation (SCT) therapy and regenerative medicine, reported
today the successful results of a case of stem cell transplantation
performed last November on a 42-year-old man, who was diagnosed with
progressive multiple sclerosis (MS) three years ago.



Samuel Bonnar, a shop owner in Newtownabbey, Ireland, was experiencing
increasing debilitation including difficulty speaking and the effects of
poor circulation. He needed crutches to walk and was able to climb stairs
only by lifting his left leg with his arm with each step. He had received
traditional treatment for MS at two hospitals in Ireland with little to no
effect. The traditional prognosis for MS victims is ever-increasing
debilitation leading to death.



Calvin Cao, CEO of Stem Cell Therapy International (SCTI), said Mr. Bonnar
sought alternative treatment for his condition, first learning about stem
cell transplantation therapy in the United Kingdom from the non-profit
newsletter, "Different Strokes," that detailed the positive treatment of
Belfast native Ian McBride, who had suffered a stroke and was successfully
treated with stem cell transplantation at the SCTI affiliated medical
facility in 2005.





Calvin Cao said SCTI arranged for Mr. Bonnar to be treated with injections
of a stem cell biological solution at the SCTI affiliate medical facility
in Kiev, Ukraine on November 27th, 2005. "The positive results of the
therapy were remarkable and almost instant," Mr. Cao reported. "Within a
few days, Mr. Bonnar's speech and mobility were vastly improved and after
two weeks he had regained the ability to climb a full set of stairs without
having to lift his left leg with his hand. Numbness in the fingertips of
both hands subsided and occurs now only occasionally."



In a correspondence with SCTI in mid-December, Mr. Bonnar recounted the
results: "After the treatment, my speech improved dramatically. It is
almost back to the way it was. Other people have commented on the dramatic
difference. The doctors at the hospital said it would take two-to-three
months to see the full effect of the stem cell transplantation therapy. It
has now been 2 1/2 weeks since the treatment and already there is
noticeable improvement."



SCTI has posted a video clip on its web site made in Kiev that shows Sam
Bonnar describing his condition both before and after the treatment. To
view the video clip, go to: http://www.scticorp.com/sam.cfm.



Calvin Cao said Mr. Bonar's progress will be monitored over the next six
months. There is no follow-up treatment planned at this time. He said that
Dr. Weinwen Deng, Ph.D., an expert in stem cell therapy from Tulane
University and a member of the SCTI Medical and Scientific Advisory Board,
has been asked to prepare a scientific abstract on the case and submit it
to an appropriate scientific journal for publication.



"Sam Bonnar's improvement, along with Ian McBride's, provides increasing
evidence of the efficacy of stem cell transplantation therapy and, we
believe, will encourage stem cell researchers worldwide to promote
widespread acceptance of stem cell therapy worldwide," Mr. Cao said.



He said, "The stem cell therapy procedure Mr. Bonnar received at the clinic
is based on the use of the stem cell biological solution, which is part of
the exclusive license agreement SCTI has for the use of 26 patents related
to stem cell technology from the Institute of Cell Therapy (ICT). Mr.
Bonnar's is another successful case we have treated using our stem cell
biological solution and the results have exceeded our expectations."



With the enactment of Proposition 71 in California in November 2004, a fund
of $3 Billion was created to fund stem cell research. Since then four other
states, New Jersey, Connecticut, Illinois and Wisconsin, have allocated
funds for stem cell research. For additional information about SCTI and its
stem cell treatment procedures, you can visit their website @
www.scticorp.com.



About Stem Cell Therapy International



Stem Cell Therapy International, Inc. is engaged in the field of research
and development of regenerative medicine. SCTI manufactures allo stem cell
biological solutions that are currently being used in the treatment of
patients suffering from degenerative disorders of the human body such as
Alzheimer's, Parkinson's Disease, ALS, leukemia, muscular dystrophy,
multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke,
heart disease, liver and retinal disease, diabetes as well as certain types
of cancer. The Company has established agreements with highly specialized,
professional medical treatment facilities around the world in locations
where stem cell transplantation therapy is approved by the appropriate
local government agencies. SCTI intends to provide these biological
solutions containing stem cell products in the United States to
universities, institutes and privately funded laboratory facilities for
research purposes and clinical trials. Its products, which are available
now, include various allo stem cell biological solutions containing (human
stem cells), low-molecular proteins and human growth factor hormones.



Forward-Looking Statements



This report includes "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934. The information in this news release
includes certain forward-looking statements that are based upon assumptions
that in the future may prove not to have been accurate and are subject to
significant risks and uncertainties, including statements as to the future
performance of the company. Although the company believes that the
expectations reflected in its forward-looking statements are reasonable, it
can give no assurance that such expectations or any of its forward-looking
statements will prove to be correct. Factors that could cause results to
differ include, but are not limited to, successful performance of internal
plans, product development acceptance, and the impact of competitive
services and pricing and general economic risks and uncertainties.



For more information, please contact:

Stem Cell Therapy International, Inc.
Calvin Cao
Chairman and CEO
Stem Cell Therapy International, Inc.
E: [e-mail]

Investor Relations
Arun Chakraborty
Investor Relations
Stern & Co.
T: 212-888-0044
E: [e-mail]

Media Relations
Stan Froelich
VP, Media Relations
Stern & Co.
T: 212-888-0044
E: [e-mail]